TAH4411
Chemotherapy‑induced nausea (Antiemetic)
CommercialApproved in Japan
Key Facts
Indication
Chemotherapy‑induced nausea (Antiemetic)
Phase
Commercial
Status
Approved in Japan
Company
About TAHO Pharmaceuticals
TAHO Pharma delivers novel transdermal and oral‑film drug formats to address unmet patient needs across cardiovascular, neurology, and oncology markets.
View full company profile